The present invention pertains generally to the field of therapeutic compds., and more specifically to certain compds. of the following formula (I) (for convenience, collectively referred to herein as "IP compds."), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterized by (e.g., driven by) mutant RAS ("mutant RAS cancer"). The present invention also pertains to pharmaceutical compns. comprising such compds., and the use of such compds. and compns. in the treatment of cancer, e.g., mutant RAS cancer.
1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy / Springer, Caroline; Niculescu-Duvaz, Ion; Marais, Richard; Niculescu-Duvaz, Dan; Zambon, Alfonso; Menard, Delphine. - (2011 Jan 27).
1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
Zambon, Alfonso;
2011
Abstract
The present invention pertains generally to the field of therapeutic compds., and more specifically to certain compds. of the following formula (I) (for convenience, collectively referred to herein as "IP compds."), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterized by (e.g., driven by) mutant RAS ("mutant RAS cancer"). The present invention also pertains to pharmaceutical compns. comprising such compds., and the use of such compds. and compns. in the treatment of cancer, e.g., mutant RAS cancer.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
